Latest Insider Transactions at Nuvation Bio Inc. (NUVB)
This section provides a real-time view of insider transactions for Nuvation Bio Inc. (NUVB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Nuvation Bio Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Nuvation Bio Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 08
2024
|
Robert Mashal |
BUY
Open market or private purchase
|
Indirect |
100,000
+50.0%
|
$200,000
$2.2 P/Share
|
|
Sep 04
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
BUY
Conversion of derivative security
|
Indirect |
1,695,700
+43.01%
|
-
|
|
Sep 04
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
BUY
Conversion of derivative security
|
Direct |
2,543,600
+39.34%
|
-
|
|
Sep 04
2024
|
Xiangmin Cui |
BUY
Conversion of derivative security
|
Indirect |
19,004,200
+42.14%
|
-
|
|
Jun 25
2024
|
Xiangmin Cui |
BUY
Open market or private purchase
|
Indirect |
277,895
+10.18%
|
$555,790
$2.97 P/Share
|
|
Jun 24
2024
|
Xiangmin Cui |
BUY
Open market or private purchase
|
Indirect |
336,874
+13.41%
|
$673,748
$2.98 P/Share
|
|
Jun 21
2024
|
Xiangmin Cui |
BUY
Open market or private purchase
|
Indirect |
75,411
+3.94%
|
$226,233
$3.0 P/Share
|
|
Jun 20
2024
|
Xiangmin Cui |
BUY
Open market or private purchase
|
Indirect |
87,715
+4.74%
|
$175,430
$2.99 P/Share
|
|
Jun 11
2024
|
Kim D Blickenstaff |
BUY
Open market or private purchase
|
Indirect |
172,189
+50.0%
|
$344,378
$2.9 P/Share
|
|
May 24
2024
|
Daniel G Welch |
BUY
Exercise of conversion of derivative security
|
Direct |
659,947
+42.86%
|
$659,947
$1.69 P/Share
|
|
Apr 09
2024
|
Xiangmin Cui |
BUY
Grant, award, or other acquisition
|
Indirect |
6,172,344
+50.0%
|
-
|
|
Apr 09
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
BUY
Grant, award, or other acquisition
|
Indirect |
550,758
+50.0%
|
-
|
|
Apr 09
2024
|
Junyuan Jerry Wang CEO, ANHEART THERAPEUTICS LTD. |
BUY
Grant, award, or other acquisition
|
Direct |
1,378,989
+50.0%
|
-
|
|
Feb 21
2023
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
53,000
+0.42%
|
$53,000
$1.36 P/Share
|
|
Feb 20
2023
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
117,100
+0.92%
|
$117,100
$1.36 P/Share
|
|
Feb 19
2023
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
5,143,000
+29.14%
|
$5,143,000
$1.26 P/Share
|
|
Dec 05
2022
|
Kathryn E Falberg |
BUY
Open market or private purchase
|
Indirect |
43,000
+14.68%
|
$43,000
$1.95 P/Share
|
|
Dec 02
2022
|
Kathryn E Falberg |
BUY
Open market or private purchase
|
Indirect |
47,000
+18.5%
|
$47,000
$1.98 P/Share
|
|
Dec 01
2022
|
Kathryn E Falberg |
BUY
Open market or private purchase
|
Indirect |
84,959
+34.68%
|
$84,959
$1.97 P/Share
|
|
Nov 30
2022
|
Kathryn E Falberg |
BUY
Open market or private purchase
|
Indirect |
75,041
+50.0%
|
$75,041
$1.85 P/Share
|
|
Apr 05
2022
|
Omega Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,500,000
-10.89%
|
$12,500,000
$5.6 P/Share
|
|
Dec 15
2021
|
Omega Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
500,000
-2.13%
|
$5,000,000
$10.07 P/Share
|
|
Dec 07
2021
|
Omega Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,400,000
-5.63%
|
$12,600,000
$9.8 P/Share
|
|
Nov 24
2021
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
185,026
+2.0%
|
$1,295,182
$7.69 P/Share
|
|
Nov 23
2021
|
Omega Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
36
-0.0%
|
$324
$9.75 P/Share
|
|
Nov 22
2021
|
Omega Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
295,000
-1.17%
|
$2,655,000
$9.76 P/Share
|
|
Nov 03
2021
|
Omega Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,000,000
-7.37%
|
$18,000,000
$9.25 P/Share
|
|
Oct 29
2021
|
Omega Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
45,000
-0.17%
|
$405,000
$9.27 P/Share
|
|
Oct 28
2021
|
Omega Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,015,000
-3.6%
|
$9,135,000
$9.6 P/Share
|
|
Jul 31
2021
|
Oleg Nodelman Director |
SELL
Open market or private sale
|
Indirect |
56,598
-4.7%
|
$452,784
$8.64 P/Share
|
|
Jul 31
2021
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
56,598
+0.78%
|
$452,784
$8.64 P/Share
|
|
Apr 13
2021
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
31,500
+0.34%
|
$315,000
$10.27 P/Share
|
|
Apr 12
2021
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
133,000
+1.43%
|
$1,197,000
$9.49 P/Share
|
|
Apr 09
2021
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+3.22%
|
$3,000,000
$10.03 P/Share
|
|
Mar 31
2021
|
Oleg Nodelman Director |
BUY
Open market or private sale
|
Indirect |
151,544
+11.68%
|
$1,515,440
$10.45 P/Share
|
|
Mar 31
2021
|
Oleg Nodelman Director |
BUY
Open market or private purchase
|
Indirect |
151,544
+2.2%
|
$1,515,440
$10.45 P/Share
|
|
Mar 30
2021
|
Robert B Bazemore |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$45,000
$9.98 P/Share
|
|
Mar 02
2021
|
David Hung PRESIDENT AND CEO |
SELL
Other acquisition or disposition
|
Direct |
368,408
-0.63%
|
-
|
|
Feb 10
2021
|
Graham K Cooper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
|
Feb 10
2021
|
Faheem Hasnain Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+35.29%
|
$300,000
$10.0 P/Share
|
|
Feb 10
2021
|
Faheem Hasnain Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
|
Feb 10
2021
|
Daniel Bradbury Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
|
Feb 10
2021
|
Shalini Sharp Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+22.22%
|
$100,000
$10.0 P/Share
|
|
Feb 10
2021
|
Shalini Sharp Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+50.0%
|
-
|
|
Feb 10
2021
|
David Hung PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
58,645,012
+26.65%
|
$586,450,120
$10.0 P/Share
|
|
Feb 10
2021
|
Omega Fund V, L.P. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+1.74%
|
$5,000,000
$10.0 P/Share
|
|
Feb 10
2021
|
Omega Fund V, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
8,130,097
+22.68%
|
-
|
|
Feb 10
2021
|
Oleg Nodelman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
10,082,017
+38.77%
|
$40,328,068
$4.0 P/Share
|
|
Feb 10
2021
|
Oleg Nodelman Director |
BUY
Conversion of derivative security
|
Indirect |
2,775,000
+46.72%
|
-
|
|
Jul 06
2020
|
Eco R1 Panacea Holdings, LLC Director |
BUY
Open market or private purchase
|
Direct |
390,000
+50.0%
|
$3,900,000
$10.0 P/Share
|